Table 1 Treatment outcomes in PCV treatment trials. Adapted from previous work [98].
Study | Follow-up (months) | Treatment | Patients in trial arm (n) | Number of injections | Number of PDTs | Polyp regression rate, % | Baseline visual acuity (ETDRS letters) | Mean vision change (ETDRS letters) |
|---|---|---|---|---|---|---|---|---|
EVEREST (2012) [17] | 6 | Ranibizumab ×3 Q4W → PRN | 21 | 5.2 | 1.9 (sham) | 28.6 | 49.0 | 9.2 |
Ranibizumab ×3 Q4W + PDT → PRN | 19 | 3.9 | 1.7 | 77.8 | 57.2 | 10.9 | ||
EVEREST II (2017) [99] | 12 | Ranibizumab ×3 Q4W → PRN | 168 | 7.3 | 2.3 (sham) | 34.7 | 61.1 | 5.1 |
Ranibizumab ×3 Q4W + PDT → PRN | 154 | 5.2 | 1.5 | 69.3 | 61.2 | 8.3 | ||
EVEREST II (2020) [20] | 24 | Ranibizumab ×3 Q4W → PRN | 168 | 12.0 | – | 26.7 | 61.1 | 5.5 |
Ranibizumab ×3 Q4W + PDT → PRN | 154 | 6.0 | 2.0 | 56.6 | 61.2 | 9.6 | ||
LAPTOP (2013) [18] | 12 | Ranibizumab ×3 Q4W → PRN | 47 | 5.8 | – | Not reported | 88.0 | 4.0 |
Initial PDT → PRN | 46 | 5.2 | 1.5 | Not reported | 84.0 | −2.0 | ||
FUJISAN (2015) [38] | 12 | Ranibizumab ×3 Q4W + PDT → PRN | 37 | 4.5 | 1.1 | 62.1 | 54.3 | 8.1 |
Ranibizumab ×3 Q4W → PRN + deferred PDT | 35 | 6.8 | 1.4 | 54.8 | 54.9 | 8.8 | ||
PLANET (2018) [21] | 12 | Aflibercept ×3 Q4W → Q8W | 145 | 8.1 | 0.2 (sham) | 38.9 | 57.7 | 10.7 |
Aflibercept ×3 Q4W → Q8W + rescue PDT | 154 | 8.0 | 0.2 | 44.8 | 59.0 | 10.8 | ||
PLANET (2019) [22] | 22 | Aflibercept ×3 Q4W → Q8W | 137 | 12.7 | 0.3 (sham) | 82.1 | 57.7 | 10.7 |
Aflibercept ×3 Q4W → Q8W + rescue PDT | 147 | 12.6 | 0.3 | 85.6 | 59.0 | 9.1 |
